Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amphetamine + guanfacine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amphetamine + SPD503 is a combination therapy consisting of a psychostimulant (amphetamine or its salts) and guanfacine hydrochloride extended-release (SPD503). This combination is used in the treatment of attention-deficit/hyperactivity disorder (ADHD), particularly in children and adolescents who have an inadequate response to stimulant monotherapy. Amphetamines act as central nervous system stimulants by increasing synaptic concentrations of norepinephrine and dopamine through promoting their release and inhibiting reuptake. Guanfacine is a selective alpha-2A adrenergic receptor agonist that modulates prefrontal cortical circuits involved in attention and impulse control. The combination has been shown to improve ADHD symptoms more than either agent alone, with no significant pharmacokinetic interactions between the two drugs[1][3][7].
- Brand names
- IntunivAdderallVyvanseMydayis
- Other names
- guanfacine hydrochloride extended-release + amphetaminepsychostimulant + SPD503
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)ADRA2A (α2A)
Beyond the preview
Go deeper on amphetamine + guanfacine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amphetamine + guanfacine.